Radius Health, Inc.
(NASDAQ : RDUS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
REGNRegeneron Pharmaceuticals, Inc. 0.71%579.812.7%$671.17m
AMGNAmgen, Inc. -0.36%227.161.3%$582.50m
GILDGilead Sciences, Inc. 0.20%60.791.0%$581.98m
VRTXVertex Pharmaceuticals, Inc. 0.71%211.581.9%$512.07m
ILMNIllumina, Inc. -0.73%323.553.5%$494.75m
MRNAModerna, Inc. -0.44%70.530.0%$473.04m
ARRYArray BioPharma Inc. -4.42%42.0014.2%$403.84m
IMMUImmunomedics, Inc. 0.00%87.8611.0%$392.45m
NVAXNovavax, Inc. -0.49%93.1396.5%$309.58m
ALXNAlexion Pharmaceuticals, Inc. 1.62%121.612.0%$277.29m
BIIBBiogen, Inc. -0.68%265.001.7%$264.24m
EXASEXACT Sciences Corp. 2.44%109.7020.7%$241.86m
BNTXBioNTech SE 2.70%88.690.0%$221.27m
SRNESorrento Therapeutics, Inc. -2.42%8.081.4%$162.95m
SGENSeagen Inc. -1.86%196.926.0%$157.61m

Company Profile

Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes abaloparatide transdermal patch for potential use in osteoporosis; and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Waltham, MA.